Clinical Trial

Dominantly Inherited Alzheimer Network Trial

Study Description

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers. This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Gantenerumab

Subcutaneously every 4 weeks at escalating doses

Drug - Solanezumab

Intravenous infusion every 4 weeks at escalating doses

Drug - Matching Placebo (Gantenerumab)

Subcutaneous injection of placebo every 4 weeks

Drug - Matching Placebo (Solanezumab)

Intravenous infusion of placebo every 4 weeks

Additional Information

Official Study Title

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Clinical Trial ID

NCT01760005

ParticipAid ID

Rb462e